Sandbox Reserved 1704: Difference between revisions

Revision as of 13:52, 15 March 2022 view source Kaylin M. Todor (talk \| contribs) 77 edits No edit summary ← Older edit		Revision as of 14:17, 15 March 2022 view source Kaylin M. Todor (talk \| contribs) 77 edits No edit summary Newer edit →
Line 10:		Line 10:

	== Applications ==		== Applications ==
			Anaplastic lymphoma kinase's involvement as a proto-oncogene in various types of cancers has made it a target for drug therapies for these types of cancers. One therapeutic medication that has been increasingly used with high levels of success is Crizotinib. This medication was approved by the FDA in January of 2021 for the treatment of pediatric/young adult ALK-positive anaplastic large cell lymphoma. The treatment has an overall response rate of 90%. Crizotinib works by binding to the ATP binding site of the kinase domain. Crizotinib binds preferentially to ATP in this region and therefore can effectively block the binding of ATP. With the binding of ATP being blocked, the intercellular signaling cascade cannot begin which works to prevent the cancer from growing and spreading.

Navigation menu